Articles

Overseas Markets Beckon U.S. Hospitals

ProMedica, a nonprofit operating more than a dozen hospitals across Rust Belt communities in Ohio and Michigan, is looking to a new market to bolster its anemic growth: China.
 Executives and staff from the Toledo-based nonprofit have been touring hospitals in Shanghai, Shenzhen and Chengdu, exploring possible deals in the world's second largest economy that they hope will help offset weak revenue growth at home.

FDA Panel Unanimously Backs Cannabis Drug for Severe Epilepsy

A US Food and Drug Administration (FDA) advisory committee has voted unanimously to support approval of a purified formulation of cannabidiol (Epidiolex, GW Pharmaceuticals) as an adjunctive treatment for Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) in patients 2 years of age or older.

USPSTF: Exercise, Not Supplements, for Preventing Falls

Updated recommendations from the US Preventive Services Task Force (USPSTF) continue to support exercise and multifactorial interventions to prevent falls in community-dwelling adults aged 65 years or older, but advise against vitamin D supplementation, according to two statements published online today in JAMA.

Strawberries Number 1 (Again) on 'Dirty Dozen' List

Strawberries once again top the annual ''Dirty Dozen" list of produce found with the most pesticides.

And once again, experts not involved in the report say they worry the list will discourage people from eating fruits and vegetables, especially people on budgets who view higher-priced organic produce as unaffordable.

Two New Drug Classes Tied to Better Survival in Type 2 Diabetes

Patients with type 2 diabetes who did not achieve adequate glycemic control with metformin had improved survival during follow-up if they received add-on therapy with a sodium-glucose cotransporter 2 (SGLT-2) inhibitor or a glucagon-like peptide 1 (GLP-1) agonist rather than a dipeptidyl peptidase-4 (DPP-4) inhibitor or control (placebo or no treatment), in a network meta-analysis that indirectly compared these three drug classes.

Rates of heart failure and myocardial infarction (MI) were also lower in patients who received SGLT-2 inhibitors rather than controls.